Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
Clinical trial NCT05677971 · RECRUITING
Trial details
- NCT number
- NCT05677971
- Sponsor
- Takeda
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-06
- Primary completion
- 2029-01-17
- Enrollment
- 160
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.